Skip to main content
SpringerLink
Log in

MicroRNA-3692-3p is overexpressed in lung tumors but may not serve as a prognostic biomarker in lung cancer patients

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

We previously reported overexpression of miR-3692-3p in the serum of non-small cell lung cancer patients. However, the expression profile and clinical utility of miR-3692-3p in the tumor tissues of lung cancer patients are not yet reported.

Methods and results

We quantified the expression levels of miR-3692-3p in the tumors and adjacent normal lung tissues of early-stage (n = 29) and tissue biopsies of locally advanced and metastatic (n = 85) lung cancer patients using TaqMan advanced miRNA assay. We correlated miR-3692-3p expression with survival outcomes, therapeutic response, and other clinicopathological variables. We also predicted the target genes of miR-3692-3p, constructed a protein–protein interaction network, and performed functional enrichment analysis using various in silico tools. We found significant overexpression of miR-3692-3p in the tumors (Log2 fold change = 3.672; p < 0.0001) and tissue biopsies (Log2 fold change = 2.08; p = 0.0001) compared to normal lung tissues of lung cancer patients. The expression of miR-3692-3p did not correlate with overall survival (OS), progression-free survival (PFS), and response to therapy. In multivariate analysis, therapeutic response emerged as an independent prognostic biomarker of OS (HR = 3.47; p = 0.022) and PFS (HR = 19.86; p < 0.001). Our in silico analysis predicted 238 target genes of miR-3692-3p.

Conclusions

Overexpression of miR-3692-3p could contribute to the development of lung cancer. However, mechanistic studies are warranted to shed further light on its role in lung carcinogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bartel DP (2004) MicroRNAs. Cell 116:281–297. https://doi.org/10.1016/S0092-8674(04)00045-5

    Article  CAS  Google Scholar 

  2. Alles J, Fehlmann T, Fischer U et al (2019) An estimate of the total number of true human miRNAs. Nucleic Acids Res 47:3353–3364. https://doi.org/10.1093/nar/gkz097

    Article  CAS  Google Scholar 

  3. Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK (2016) miRNA Deregulation in cancer cells and the tumor microenvironment. Cancer Discov 6:235–246. https://doi.org/10.1158/2159-8290.CD-15-0893

    Article  CAS  Google Scholar 

  4. Singh DK, Bose S, Kumar S (2016) Role of microRNA in regulating cell signaling pathways, cell cycle, and apoptosis in non-small cell lung cancer. Curr Mol Med 16:474–486. https://doi.org/10.2174/1566524016666160429120702

    Article  CAS  Google Scholar 

  5. Harrandah AM, Mora RA, Chan EKL (2018) Emerging microRNAs in cancer diagnosis, progression, and immune surveillance. Cancer Lett 438:126–132. https://doi.org/10.1016/j.canlet.2018.09.019

    Article  CAS  Google Scholar 

  6. Peng Y, Croce CM (2016) The role of microRNA in human cancer. Signal Transduct Target Ther 1:15004. https://doi.org/10.1038/sigtrans.2015.4

    Article  Google Scholar 

  7. Van Roosbroeck K, Calin GA (2017) Cancer Hallmarks and MicroRNAs The Therapeutic Connection. In: Croce C, Fisher PB (eds) miRNA and Cancer. Elsevier, Amsterdam, pp 119–149

    Chapter  Google Scholar 

  8. Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics A comprehensive review. EMBO Mol Med 4:143–159. https://doi.org/10.1002/emmm.201100209

    Article  CAS  Google Scholar 

  9. He Y, Lin J, Kong D et al (2015) Current state of circulating MicroRNAs as cancer biomarkers. Clin Chem 61:1138–1155. https://doi.org/10.1373/clinchem.2015.241190

    Article  CAS  Google Scholar 

  10. Kasinski AL, Slack FJ (2011) MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11:849–864. https://doi.org/10.1038/nrc3166

    Article  CAS  Google Scholar 

  11. Kumar S, Sharawat SK, Ali A et al (2020) Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non–small cell lung cancer patients. Curr Probl Cancer 44:100540. https://doi.org/10.1016/j.currproblcancer.2020.100540

    Article  Google Scholar 

  12. Kumar S, Sharawat SK, Ali A et al (2020) Differential expression of circulating serum miR-1249-3p, miR-3195, and miR-3692-3p in non-small cell lung cancer. Hum Cell 33:839–849. https://doi.org/10.1007/s13577-020-00351-9

    Article  CAS  Google Scholar 

  13. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT (2017) The Eighth Edition Lung Cancer Stage Classification. Chest 151(1):193–203

    Article  Google Scholar 

  14. Chin C-H, Chen S-H, Wu H-H et al (2014) cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8:S11. https://doi.org/10.1186/1752-0509-8-S4-S11

    Article  Google Scholar 

  15. Bader GD, Hogue CW (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. https://doi.org/10.1186/1471-2105-4-2

    Article  Google Scholar 

  16. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  Google Scholar 

  17. He Z, Yi J, Liu X et al (2016) MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Mol Cancer 15:51. https://doi.org/10.1186/s12943-016-0533-3

    Article  CAS  Google Scholar 

  18. Kim BG, Kang S, Han HH et al (2016) Transcriptome-wide analysis of compression-induced microRNA expression alteration in breast cancer for mining therapeutic targets. Oncotarget 7(19):27468–27478. https://doi.org/10.18632/oncotarget.8322

    Article  Google Scholar 

  19. Stückrath I, Rack B, Janni W et al (2015) Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget 6(15):13387–13401. https://doi.org/10.18632/oncotarget.3874

    Article  Google Scholar 

  20. Yasui T, Yanagida T, Ito S et al (2017) Unveiling massive numbers of cancer-related urinary-microRNA candidates via nanowires. Sci Adv. https://doi.org/10.1126/sciadv.1701133

    Article  Google Scholar 

  21. Stuopelytė K, Daniūnaitė K, Jankevičius F, Jarmalaitė S (2016) Detection of miRNAs in urine of prostate cancer patients. Medicina 52:116–124. https://doi.org/10.1016/j.medici.2016.02.007

    Article  Google Scholar 

  22. Wu D, Tang R, Qi Q et al (2015) Five functional polymorphisms of B7/CD28 co-signaling molecules alter susceptibility to colorectal cancer. Cell Immunol 293:41–48. https://doi.org/10.1016/j.cellimm.2014.11.006

    Article  CAS  Google Scholar 

  23. Marinelli O, Nabissi M, Morelli MB et al (2018) ICOS-L as a potential therapeutic target for cancer immunotherapy. Curr Protein Pept Sci 19:1107–1113. https://doi.org/10.2174/1389203719666180608093913

    Article  CAS  Google Scholar 

  24. Soldevilla MM, Villanueva H, Meraviglia-Crivelli D et al (2019) ICOS Costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity. Mol Ther 27:1878–1891. https://doi.org/10.1016/j.ymthe.2019.07.013

    Article  CAS  Google Scholar 

Download references

Funding

This study is supported by an extramural research grant from the Indian Council of Medical Research (ICMR), New Delhi (Grant No. 5/13/11/2019/NCD-III).

Author information

Author notes

  1. Vikas Gaur

    Present address: Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA

  2. Sachin Kumar and Vikas Gaur have contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    Sachin Kumar, Vikas Gaur & Ishfaq A. Mir

  2. Department of Surgical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    Jyoutishman Saikia & Sunil Kumar

Authors
  1. Sachin Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vikas Gaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ishfaq A. Mir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jyoutishman Saikia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sunil Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SK: designed and supervised the entire study. SK, VG, and IAM: performed laboratory experiments and statistical and bioinformatics analyses. JS and SK: provided clinical samples and epidemiological and survival data. All the authors contributed significantly to the writing of the manuscript. All the authors read and approved the final manuscript.

Corresponding author

Correspondence to Sachin Kumar.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The institute ethics committee approved the study (Ref. No. IEC-149/07.04.2017, RP-14/2017, and IEC-308/03.05.2019).

Consent to participation

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 94 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, S., Gaur, V., Mir, I.A. et al. MicroRNA-3692-3p is overexpressed in lung tumors but may not serve as a prognostic biomarker in lung cancer patients. Mol Biol Rep 50, 1147–1156 (2023). https://doi.org/10.1007/s11033-022-08119-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-022-08119-0

Keywords

Search

Navigation